Inflammatory breast cancer (IBC) is one of the most aggressive types of breast cancer. It can occur in women of any age. It is referred to as "inflammatory" due to its frequent presentation with symptoms resembling a skin inflammation, such as erysipelas.
The Susan G. Komen 3-Day, frequently referred to as the 3-Day, is a 60-mile walk to raise funds for Susan G. Komen for the Cure and promote awareness to fight breast cancer. Individual participants must raise at least $2,300 to walk 60 miles (96 km) over a three-day weekend.
Susan G. Komen is a breast cancer organization in the United States.
The American Association for Cancer Research (AACR) is the world's oldest and largest professional association related to cancer research. Based in Philadelphia, the AACR focuses on all aspects of cancer research, including basic, clinical, and translational research into the etiology, prevention, diagnosis, and treatment of cancer. Founded in 1907 by 11 physicians and scientists, the organization now has more than 58,000 members in 142 countries and territories. The mission of the AACR is to prevent and cure cancer through research, education, communication, collaboration, science policy and advocacy, and funding for cancer research.
Nancy Goodman Brinker is the founder of The Promise Fund and Susan G. Komen for the Cure. Brinker was also United States Ambassador to Hungary from 2001 to 2003 and Chief of Protocol of the United States from 2007 to the end of the George W. Bush administration. In 2011, she was appointed a Goodwill Ambassador for Cancer Control by the World Health Organization.
Richard G. Pestell is an Australian American oncologist, endocrinologist and research scientist. Pestell was appointed an Officer of the Order of Australia for distinguished service to medicine and medical education in 2019 by Queen Elizabeth II. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. He founded six biotechnology companies developing cancer therapy and diagnostics. He is currently Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute.
The Komen Brinker Award for Scientific Distinction was established by Susan G. Komen for the Cure in 1992 to recognize leading scientists for their significant work in advancing research concepts or clinical application in the fields of breast cancer research, screening or treatment.
Breast Cancer Awareness Month (BCAM), also referred to in the United States as National Breast Cancer Awareness Month (NBCAM), is an annual international health campaign organized by major breast cancer charities every October to increase awareness of the disease and raise funds for research into its cause, prevention, diagnosis, treatment, and cure.
Triple-negative breast cancer (TNBC) is any breast cancer that either lacks or shows low levels of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) overexpression and/or gene amplification. Triple-negative is sometimes used as a surrogate term for basal-like.
The breast cancer research stamp (BCRS) is a semi-postal non-denominated postage stamp issued by the United States Postal Service, priced in 2011 as eleven cents higher than the standard first-class letter rate. The surplus above the price of the first-class stamp is collected by the United States Postal Service (USPS) and allocated to the National Institutes of Health (NIH) and the Department of Defense (DoD) for breast cancer research.
Living Beyond Breast Cancer (LBBC), is a national 501(c)(3) nonprofit organization headquartered in Bala Cynwyd, just outside Philadelphia, Pennsylvania, in the United States. LBBC works with women who have been diagnosed with breast cancer and their caregivers throughout their experience of diagnosis, treatment and recovery. Their goal to be a "high-touch organization" that provides people with information and support of relevance to their personal experience of breast cancer. The organization supports studies of health care that are sensitive to issues of ethnicity, age, sexual orientation, and diagnosis.
Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19, triple negative breast cancer, and HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. In February 2008, the drug entered Phase 2 clinical trials and a phase 3 trial was begun in 2015. In February 2018, Cytodyn Inc reported that the primary endpoint had been achieved in the PRO 140 pivotal combination therapy trial in HIV infection. In 2020 CytoDyn submitted a fast-track biologics license application for treatment of CCR5-tropic HIV-1 Infection.
The Breast Cancer Research Foundation (BCRF) is an independent, not-for-profit organization which has raised $569.4 million to support clinical and translational research on breast cancer at medical institutions in the United States and abroad. BCRF currently funds over 255 researchers in 14 countries.
Team Heather is a fundraising group in the Susan G. Komen for the Cure Global Race for the Cure in Washington, D.C., which has raised over $403,000, since June, 2001, for Susan G. Komen for the Cure and breast cancer research, education, screening, and treatment. Team Heather was formed in 2001 to support 25-year-old Heather Gardner (Starcher) (1976–2002), as she began her fight against breast cancer – a fight that ended on September 29, 2002.
Glembatumumab vedotin is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).
Eric P. Winer is a medical oncologist and clinical researcher specializing in breast cancer. He is director of Yale Cancer Center and president and physician-in-chief of Smilow Cancer Hospital Yale New Haven Health System, effective February 1, 2022. He also is Deputy Dean for Cancer Research at Yale School of Medicine. From 1997 to 2021, he was the Chief of the Breast Oncology Program at Dana–Farber Cancer Institute in Boston, Massachusetts. Beginning in 2013, he held a range of institutional roles at Dana-Farber, including Chief of Clinical Development, the Thompson Chair in Breast Cancer Research and Director of the Dana-Farber/Harvard SPORE in Breast Cancer. He also served as a Professor of Medicine at Harvard Medical School. He was president of the American Society of Clinical Oncology (ASCO) 2022-2023 and became Chair of the Board in mid-June 2023. His career has been focused on breast cancer treatment and research.
Pinkwashing is a form of cause marketing that uses a pink ribbon logos. The companies display the pink ribbon logo on products that are known to cause different types of cancer. The Pink ribbon logo symbolizes support for breast cancer-related charities or foundations.
Atezolizumab, sold under the brand name Tecentriq among others, is a monoclonal antibody medication used to treat urothelial carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma and alveolar soft part sarcoma, but discontinued for use in triple-negative breast cancer (TNBC). It is a fully humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death-ligand 1 (PD-L1).
Sacituzumab govitecan, sold under the brand name Trodelvy by Gilead Sciences, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer.
Katherine A. Hoadley is an American breast cancer researcher. As of 2017, she has served as the Associate Director of Cancer Genomics for the High-Throughput Sequencing Facility at UNC Lineberger Comprehensive Cancer Center. Her research is focused on understanding the biology of cancer through gene expression analyses and integrative genomic approaches.
